{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:19:56Z","timestamp":1791519596548,"version":"4.3.4"},"reference-count":35,"publisher":"Walter de Gruyter GmbH","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Background<\/jats:bold>\n                    : Multimodal therapeutic strategies have improved the outcome of peritoneal metastases (PM). However, objective assessment of therapy response remains difficult in PM, since radiological studies have a poor accuracy for low-volumetric disease. There is an obvious need for a histological gold standard allowing assessment of tumor response to treatment in PM.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Content<\/jats:bold>\n                    : We propose to perform peritoneal punch biopsies with a diameter of 3 to 5\u2006mm in all four abdominal quadrants. We propose a four-tier Peritoneal Regression Grading Score (PRGS), defined as Grade 1: complete response (absence of tumor cells), Grade 2: major response (major regression features, few residual tumor cells), Grade 3: minor response (some regressive features but predominance of residual tumor cells), Grade 4: no response (tumor cells without any regressive features). Acellular mucin and infarct-like necrosis should be regarded as regression features. We recommend reporting the mean and the worst value of the regression grades obtained. When complete tumor response is suspected intraoperatively, a peritoneal cytology should be sampled.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Summary<\/jats:bold>\n                    : A generic, unique score for the assessment of histological tumor response to chemotherapy in PM makes sense because of the clinical impact of histological response to therapy and because the organ of metastasis (peritoneum) is the same. By adopting PRGS, different centers will be able to use a uniform terminology and grading that will allow meaningful comparison of their results.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Outlook<\/jats:bold>\n                    : PRGS has now to be validated in several gastrointestinal and gynecological cancer types and may be useful both in clinical and research settings.\n                  <\/jats:p>","DOI":"10.1515\/pp-2016-0011","type":"journal-article","created":{"date-parts":[[2016,6,7]],"date-time":"2016-06-07T06:01:31Z","timestamp":1465279291000},"page":"99-107","source":"Crossref","is-referenced-by-count":172,"title":["Peritoneal sampling and histological assessment of therapeutic response in peritoneal metastasis: proposal of the Peritoneal Regression Grading Score (PRGS)"],"prefix":"10.1515","volume":"1","author":[{"given":"Wiebke","family":"Solass","sequence":"first","affiliation":[{"name":"Institute of Pathology, Medical School Hanover, Hanover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Sempoux","sequence":"additional","affiliation":[{"name":"Department of Pathology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f6nke","family":"Detlefsen","sequence":"additional","affiliation":[{"name":"Department of Pathology, Odense University Hospital, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman J.","family":"Carr","sequence":"additional","affiliation":[{"name":"Peritoneal Malignancy Institute, Basingstoke and North Hampshire Hospital, Basingstoke, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Bibeau","sequence":"additional","affiliation":[{"name":"Department of Pathology, National Networks of Rare Periteoneal Tumors (RENAPE) and of digestive peritoneal carcinomatosis (BIG-REBNAPE), Institute du Cancer de Montpellier, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2016,6,7]]},"reference":[{"key":"2025120909210685135_j_pp-2016-0011_ref_001_w2aab3b7b5b1b6b1ab1b9b1Aa","doi-asserted-by":"crossref","unstructured":"1. Thies S, Langer R. Tumor regression grading of gastrointestinal carcinomas after neoadjuvant treatment. Front Oncol 2013 7;3:262.","DOI":"10.3389\/fonc.2013.00262"},{"key":"2025120909210685135_j_pp-2016-0011_ref_002_w2aab3b7b5b1b6b1ab1b9b2Aa","unstructured":"2. protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum. College of American Pathologists 2016. http:\/\/www.cap.org\/ShowProperty?nodePath=\/UCMCon\/Contribution%20Folders\/WebContent\/pdf\/cp-colon-16protocol-3400.pdf."},{"key":"2025120909210685135_j_pp-2016-0011_ref_003_w2aab3b7b5b1b6b1ab1b9b3Aa","doi-asserted-by":"crossref","unstructured":"3. Rubbia-Brandt L, Giostra E, Brezault C, Roth AD, Andres A, Audard V, et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol 2007;18:299\u2013304.","DOI":"10.1093\/annonc\/mdl386"},{"key":"2025120909210685135_j_pp-2016-0011_ref_004_w2aab3b7b5b1b6b1ab1b9b4Aa","doi-asserted-by":"crossref","unstructured":"4. Blazer DG, Kishi Y, Maru DM, Kopetz S, Chun YS, Overman MJ, et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 2008;26:5344\u201351.","DOI":"10.1200\/JCO.2008.17.5299"},{"key":"2025120909210685135_j_pp-2016-0011_ref_005_w2aab3b7b5b1b6b1ab1b9b5Aa","doi-asserted-by":"crossref","unstructured":"5. Chang HHL, Leeper WR, Chan G, Quan D, Driman DK. Infarct-like necrosis: a distinct form of necrosis seen in colorectal carcinoma liver metastases treated with perioperative chemotherapy. Am J Surg Pathol 2012;36:570\u20136.","DOI":"10.1097\/PAS.0b013e31824057e7"},{"key":"2025120909210685135_j_pp-2016-0011_ref_006_w2aab3b7b5b1b6b1ab1b9b6Aa","doi-asserted-by":"crossref","unstructured":"6. Gould N, Sill MW, Mannel RS, Thaker PH, DiSilvestro PA, Waggoner SE, et\u2009al. A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2012;127:506\u201310.","DOI":"10.1016\/j.ygyno.2012.08.037"},{"key":"2025120909210685135_j_pp-2016-0011_ref_007_w2aab3b7b5b1b6b1ab1b9b7Aa","doi-asserted-by":"crossref","unstructured":"7. Verwaal VJ, van Ruth S, Witkamp A, Boot H, van Slooten G, Zoetmulder FA. Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 2005;12:65\u201371.","DOI":"10.1007\/s10434-004-1167-z"},{"key":"2025120909210685135_j_pp-2016-0011_ref_008_w2aab3b7b5b1b6b1ab1b9b8Aa","doi-asserted-by":"crossref","unstructured":"8. Go\u00e9r\u00e9 D, Malka D, Tzanis D, Gava V, Boige V, Eveno C, et\u2009al. Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy? Ann Surg 2013;257:1065\u201371.","DOI":"10.1097\/SLA.0b013e31827e9289"},{"key":"2025120909210685135_j_pp-2016-0011_ref_009_w2aab3b7b5b1b6b1ab1b9b9Aa","doi-asserted-by":"crossref","unstructured":"9. Passot G, You B, Boschetti G, Fontaine J, Isaac S, Decullier E, et\u2009al. Pathological response to neoadjuvant chemotherapy: a new prognosis tool for the curative management of peritoneal colorectal carcinomatosis. Ann Surg Oncol 2014;21:2608\u201314.","DOI":"10.1245\/s10434-014-3647-0"},{"key":"2025120909210685135_j_pp-2016-0011_ref_010_w2aab3b7b5b1b6b1ab1b9c10Aa","doi-asserted-by":"crossref","unstructured":"10. Tempfer CB, Winnekendonk G, Solass W, Horvat R, Giger-Pabst U, Zieren J, et\u2009al. Pressurized intraperitoneal aerosol chemotherapy in women with recurrent ovarian cancer: A phase 2 study. Gynecol Oncol 2015;137:223\u20138.","DOI":"10.1016\/j.ygyno.2015.02.009"},{"key":"2025120909210685135_j_pp-2016-0011_ref_011_w2aab3b7b5b1b6b1ab1b9c11Aa","doi-asserted-by":"crossref","unstructured":"11. Lambert LA. Looking up: Recent advances in understanding and treating peritoneal carcinomatosis. CA Cancer J Clin 2015;65:284\u201398.","DOI":"10.3322\/caac.21277"},{"key":"2025120909210685135_j_pp-2016-0011_ref_012_w2aab3b7b5b1b6b1ab1b9c12Aa","doi-asserted-by":"crossref","unstructured":"12. Klaver YL, Hendriks T, Lomme RM, Rutten HJ, Bleichrodt RP, de Hingh IH. Intraoperative versus early postoperative intraperitoneal chemotherapy after cytoreduction for colorectal peritoneal carcinomatosis: an experimental study. Ann Surg Oncol 2012;19:475\u201382.","DOI":"10.1245\/s10434-011-1984-9"},{"key":"2025120909210685135_j_pp-2016-0011_ref_013_w2aab3b7b5b1b6b1ab1b9c13Aa","doi-asserted-by":"crossref","unstructured":"13. Yonemura Y, Canbay E, Ishibashi H. Prognostic factors of peritoneal metastases from colorectal cancer following cytoreductive surgery and perioperative chemotherapy. ScientificWorldJournal 2013 Apr 18;2013:978394.","DOI":"10.1155\/2013\/978394"},{"key":"2025120909210685135_j_pp-2016-0011_ref_014_w2aab3b7b5b1b6b1ab1b9c14Aa","doi-asserted-by":"crossref","unstructured":"14. Bijelic L, Stuart OA, Sugarbaker P. Adjuvant bidirectional chemotherapy with intraperitoneal pemetrexed combined with intravenous Cisplatin for diffuse malignant peritoneal mesothelioma. Gastroenterol Res Pract 2012;2012:890450.","DOI":"10.1155\/2012\/890450"},{"key":"2025120909210685135_j_pp-2016-0011_ref_015_w2aab3b7b5b1b6b1ab1b9c15Aa","doi-asserted-by":"crossref","unstructured":"15. Solass W, Kerb R, M\u00fcrdter T, et al. Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. Ann Surg Oncol 2014;21:553\u20139.","DOI":"10.1245\/s10434-013-3213-1"},{"key":"2025120909210685135_j_pp-2016-0011_ref_016_w2aab3b7b5b1b6b1ab1b9c16Aa","doi-asserted-by":"crossref","unstructured":"16. Demtr\u00f6der C, Solass W, Zieren J, Strumberg D, Giger-Pabst U, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with oxaliplatin in colorectal peritoneal metastasis. Colorectal Dis 2015 Sep 24. doi: 10.1111\/codi.13130. [Epub ahead of print].","DOI":"10.1111\/codi.13130"},{"key":"2025120909210685135_j_pp-2016-0011_ref_017_w2aab3b7b5b1b6b1ab1b9c17Aa","doi-asserted-by":"crossref","unstructured":"17. Nadiradze G, Giger-Pabst U, Zieren J, Strumberg D, Solass W, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with low-dose cisplatin and doxorubicin in gastric peritoneal metastasis. J Gastrointest Surg 2016;20:367\u201373.","DOI":"10.1007\/s11605-015-2995-9"},{"key":"2025120909210685135_j_pp-2016-0011_ref_018_w2aab3b7b5b1b6b1ab1b9c18Aa","unstructured":"18. Sugarbaker PH. Management of peritoneal metastases \u2013 Basic concepts. J BUON 2015 May;20 Suppl 1:S2-11. Review. PubMed PMID: 26051329."},{"key":"2025120909210685135_j_pp-2016-0011_ref_019_w2aab3b7b5b1b6b1ab1b9c19Aa","doi-asserted-by":"crossref","unstructured":"19. Leblanc E, Sonoda Y, Narducci F, Ferron G, Querleu D. Laparoscopic staging of early ovarian carcinoma. Curr Opin Obstet Gynecol 2006;18:407\u201312.","DOI":"10.1097\/01.gco.0000233935.51801.48"},{"key":"2025120909210685135_j_pp-2016-0011_ref_020_w2aab3b7b5b1b6b1ab1b9c20Aa","doi-asserted-by":"crossref","unstructured":"20. Kikuchi H, Kamiya K, Hiramatsu Y, Miyazaki S, Yamamoto M, Ohta M, et\u2009al. Laparoscopic narrow-band imaging for the diagnosis of peritoneal metastasis in gastric cancer. Ann Surg Oncol 2014;21:3954\u201362.","DOI":"10.1245\/s10434-014-3781-8"},{"key":"2025120909210685135_j_pp-2016-0011_ref_021_w2aab3b7b5b1b6b1ab1b9c21Aa","doi-asserted-by":"crossref","unstructured":"21. Bibeau F, Gil H, Castan F, et al. Comment on \u201cHistopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab\u201d. Br J Cancer 2013;109:3127\u20139.","DOI":"10.1038\/bjc.2013.651"},{"key":"2025120909210685135_j_pp-2016-0011_ref_022_w2aab3b7b5b1b6b1ab1b9c22Aa","doi-asserted-by":"crossref","unstructured":"22. Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, et\u2009al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 2003;98:1521\u201330.","DOI":"10.1002\/cncr.11660"},{"key":"2025120909210685135_j_pp-2016-0011_ref_023_w2aab3b7b5b1b6b1ab1b9c23Aa","doi-asserted-by":"crossref","unstructured":"23. Schirripa M, Loupakis F, Pollina L, et al. Reply: Comment on \u201cHistopathologic evaluation of liver metastases from colorectal cancer patients treated with FOLFOXIRI plus bevacizumab\u201d. Br J Cancer 2013;109:3129\u201330.","DOI":"10.1038\/bjc.2013.652"},{"key":"2025120909210685135_j_pp-2016-0011_ref_024_w2aab3b7b5b1b6b1ab1b9c24Aa","doi-asserted-by":"crossref","unstructured":"24. Chirieac LR, Swisher SG, Correa AM, et al. Signet-ring cell or mucinous histology after preoperative chemoradiation and survival in patients with esophageal or esophagogastric junction adenocarcinoma. Clin Cancer Res 2005;11:2229\u201336.","DOI":"10.1158\/1078-0432.CCR-04-1840"},{"key":"2025120909210685135_j_pp-2016-0011_ref_025_w2aab3b7b5b1b6b1ab1b9c25Aa","doi-asserted-by":"crossref","unstructured":"25. Shia J, McManus M, Guillem JG, et al. Significance of acellular mucin pools in rectal carcinoma after neoadjuvant chemoradiotherapy. Am J Surg Pathol 2011;35:127\u201334.","DOI":"10.1097\/PAS.0b013e318200cf78"},{"key":"2025120909210685135_j_pp-2016-0011_ref_026_w2aab3b7b5b1b6b1ab1b9c26Aa","doi-asserted-by":"crossref","unstructured":"26. Shia J, Guillem JG, Moore HG, et al. Patterns of morphologic alteration in residual rectal carcinoma following preoperative chemoradiation and their association with long-term outcome. Am J Surg Pathol 2004;28:215\u201323.","DOI":"10.1097\/00000478-200402000-00009"},{"key":"2025120909210685135_j_pp-2016-0011_ref_027_w2aab3b7b5b1b6b1ab1b9c27Aa","doi-asserted-by":"crossref","unstructured":"27. Smith KD, Tan D, Das P, et al. Clinical significance of acellular mucin in rectal adenocarcinoma patients with a pathologic complete response to preoperative chemoradiation. Ann Surg 2010;251:261\u20134.","DOI":"10.1097\/SLA.0b013e3181bdfc27"},{"key":"2025120909210685135_j_pp-2016-0011_ref_028_w2aab3b7b5b1b6b1ab1b9c28Aa","doi-asserted-by":"crossref","unstructured":"28. Lim S-B, Hong S-M, Yu CS, et al. Prevalence and clinical significance of acellular mucin in locally advanced rectal cancer patients showing pathologic complete response to preoperative chemoradiotherapy. Am J Surg Pathol 2013;37:47\u201352.","DOI":"10.1097\/PAS.0b013e3182657186"},{"key":"2025120909210685135_j_pp-2016-0011_ref_029_w2aab3b7b5b1b6b1ab1b9c29Aa","doi-asserted-by":"crossref","unstructured":"29. Fern\u00e1ndez-Ace\u00f1ero MJ, Granja M, Sastre J, Garc\u00eda-Paredes B, Estrada L. Prognostic significance of tumor regression in lymph nodes after neoadjuvant therapy for rectal carcinoma. Virchows Arch 2016 Jan 11. [Epub ahead of print].","DOI":"10.1007\/s00428-015-1901-x"},{"key":"2025120909210685135_j_pp-2016-0011_ref_030_w2aab3b7b5b1b6b1ab1b9c30Aa","doi-asserted-by":"crossref","unstructured":"30. Chang F, Deere H, Mahadeva U, George S. Histopathologic examination and reporting of esophageal carcinomas following preoperative neoadjuvant therapy: practical guidelines and current issues. Am J Clin Pathol 2008;129:252\u201362.","DOI":"10.1309\/CCR3QN4874YJDJJ7"},{"key":"2025120909210685135_j_pp-2016-0011_ref_031_w2aab3b7b5b1b6b1ab1b9c31Aa","doi-asserted-by":"crossref","unstructured":"31. Pelz JO, Stojadinovic A, Nissan A, Hohenberger W, Esquivel J. Evaluation of a peritoneal surface disease severity score in patients with colon cancer with peritoneal carcinomatosis. J Surg Oncol 2009;99:9\u201315.","DOI":"10.1002\/jso.21169"},{"key":"2025120909210685135_j_pp-2016-0011_ref_032_w2aab3b7b5b1b6b1ab1b9c32Aa","doi-asserted-by":"crossref","unstructured":"32. Carr NJ, Cecil TD, Mohamed F, Sobin LH, Sugarbaker PH, Gonz\u00e1lez-Moreno S, et\u2009al. A consensus for classification and pathologic reporting of pseudomyxoma peritonei and associated appendiceal neoplasia: the results of the peritoneal surface oncology group international (PSOGI) modified Delphi process. Am J Surg Pathol 2016;40:14\u201326.","DOI":"10.1097\/PAS.0000000000000535"},{"key":"2025120909210685135_j_pp-2016-0011_ref_033_w2aab3b7b5b1b6b1ab1b9c33Aa","doi-asserted-by":"crossref","unstructured":"33. Onishi A, Akimoto T, Morishita Y, Hirahara I, Inoue M, Kusano E, et\u2009al. Peritoneal fibrosis induced by intraperitoneal methylglyoxal injection: the role of concurrent renal dysfunction. Am J Nephrol 2014;40:381\u201390.","DOI":"10.1159\/000368424"},{"key":"2025120909210685135_j_pp-2016-0011_ref_034_w2aab3b7b5b1b6b1ab1b9c34Aa","doi-asserted-by":"crossref","unstructured":"34. Aloysius MM, Zaitoun AM, Beckingham IJ, et al. The pathological response to neoadjuvant chemotherapy with FOLFOX-4 for colo- rectal liver metastases: a comparative study. Virchows Arch 2007;451:943\u20138.","DOI":"10.1007\/s00428-007-0497-1"},{"key":"2025120909210685135_j_pp-2016-0011_ref_035_w2aab3b7b5b1b6b1ab1b9c35Aa","doi-asserted-by":"crossref","unstructured":"35. Michael CM, Davidson B. Pre-analytical issues in effusion cytology. Pleura and Peritoneum 2016;1:45\u201356.","DOI":"10.1515\/pp-2016-0001"}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/pp\/1\/2\/article-p99.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2016-0011\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2016-0011\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T10:49:31Z","timestamp":1765277371000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2016-0011\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,1]]},"references-count":35,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,6,9]]},"published-print":{"date-parts":[[2016,6,1]]}},"alternative-id":["10.1515\/pp-2016-0011"],"URL":"https:\/\/doi.org\/10.1515\/pp-2016-0011","relation":{},"ISSN":["2364-768X","2364-7671"],"issn-type":[{"value":"2364-768X","type":"electronic"},{"value":"2364-7671","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6,1]]}}}